Association between insulin like growth factor-1 and lipoprotein metabolism in stable angina patients on statin therapy: a pilot study.
OBJECTIVE
The aim of this study was to test whether there was an association between systemic levels of insulin like growth factor-1 (IGF-1), IGF-1 binding protein-3 (IGFBP3) and selected parameters of lipid metabolism depending on the lipid-lowering therapy. This work was conducted in patients described by us previously who had either highly probable, or documented, coronary artery disease, and controlled serum lipids with prolonged statin therapy.


METHODS
The study was conducted among 140 patients undergoing coronary angiography. The following parameters were measured: LDL- and HDL-cholesterol levels, TG, TC, apoB-100, apoA1, Lp(a) and IGF-1 and IGFBP3, as well as the level of oxidation products of proteins and lipids.


CONCLUSIONS
In the group of patients with LDL target up to 100 mg/dl and statins use, as well as in the entire population, IGF-1 and IGFBP3 were associated with protein oxidation products and Lp(a). Additionally, in the whole studied group, IGF-1 was associated with TG and LDL. More differences were observed when we used multivariate analysis. Even then, IGF-1 and IGFBP3 in the group with LDL up to 100 mg/dL, as well as in the entire group, were associated with protein oxidation products, Lp(a) and with quantitative arteriosclerosis scale (Gensini score). These results seem to confirm our previous findings, wherein significantly higher levels of systemic IGF-1 were found in patients with advanced coronary atherosclerosis.
Division of Cardiology-Intensive Therapy, Poznan University of Medical Sciences, 60–355Poznan, Poland. pab2@tlen.pl
Paweł
P
Burchardt
Piotr
P
Tabaczewski
Anna
A
Goździcka-Józefiak
Tomasz
T
Siminiak
Adam
A
Szczepaniak
Agnieszka
A
Banaszak
Henryk
H
Wysocki
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D060050:Angina, Stable / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D015227:Lipid Peroxidation / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010865:Pilot Projects
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D008074:Lipoproteins; D007334:Insulin-Like Growth Factor I